Rights and permissions
About this article
Cite this article
Denosumab more costly than zoledronic acid in mBC. Pharmacoecon. Outcomes News 639, 7 (2011). https://doi.org/10.2165/00151234-201106390-00015
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201106390-00015